Vesilut
Bladder bioregulator
Vesilut (Bladder bioregulator) is a longevity & bioregulators research compound. Khavinson urinary-bladder bioregulator — proposed to support bladder cell function and urogenital aging.
Vesilut quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | Short (hrs systemically) |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Bladder cytogen (sibling to Chitomur) — course-based. The sibling to Chitomur — pick one. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, urinalysis, and how many times you get up at night. Run it as an experiment you measure, not a protocol you trust.
How Vesilut works
Khavinson urinary-bladder bioregulator — proposed to support bladder cell function and urogenital aging.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Vesilut
Buy Vesilut at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Vesilut
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- The other urinary-tract bioregulator, overlapping heavily with Chitomur in positioning. The two are indistinguishable in composition, because neither vendor publishes one — but they are no longer indistinguishable in evidence: Chitomur has a randomized blind human study indexed under its trade name and this one has none. Worth knowing before buying both.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A urinary bladder peptide preparation proposed to support bladder cell function in urogenital ageing.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- Same placebo-sensitivity caveat as Chitomur: the endpoint is symptomatic and self-reported, which is the condition under which uncontrolled evidence is least reliable.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Vesilut actually does
Correcting this site's own catalog line first. The record here has said that nothing distinguishes Vesilut from Chitomur. That is no longer accurate in 1 direction that matters: Chitomur has a randomized blind human study indexed under its trade name and Vesilut has none Gomberg 2013. The 2 products are still indistinguishable in composition, because neither publishes one. They are no longer indistinguishable in evidence.
What the preparation is. A urinary-bladder peptide complex: extracted tissue, size-fractionated, standardized by total peptide content. No sequence, therefore no formula, no exact mass, no isoelectric point, no charge to compute. The defined peptides in this catalog can be argued about numerically — Chonluten at 319.28 Da and a computed net charge near −2.06, Cardiogen at 489.50 Da and near −1.06 — and this cannot. Two lots with identical certificates of analysis can be different mixtures and no routine test — not total protein, not a peptidase digest — separates them.
The one mechanistic argument that is genuinely good here. The stated route into an epithelial cell for this family is PEPT1, described as carrying di- and tripeptides — 2 and 3 residues — and an unspecified mixture is neither Khavinson 2022. But the bladder is reached from 2 sides, and only 1 of them needs plasma clearance to work. Anything absorbed and renally cleared arrives in urine and therefore contacts urothelium from the lumen, without needing to be delivered to a deep organ by blood. That is a real anatomical argument, it applies to this product and to Chitomur and to almost nothing else in the catalog, and it has 0 experiments behind it. The transcriptional claim the class rests on Khavinson 2021 and the structural work on peptide-DNA recognition Kolchina 2019 are both about defined molecules and cannot be transferred to a mixture.
Cell, rodent, human — and where it stops
The count for this product: 0. No randomized trial, no controlled trial, no animal study, no cell study, no mechanism paper indexed under the name Vesilut.
The count for the product next to it on the shelf: 1. A randomized blind study of Chitomur in women aged 48 to 80 with overactive bladder, reading urodynamic parameters and quality of life, reporting reduced urgency and fewer urge incontinence episodes and no detected side effects Gomberg 2013. Its own abstract also reports that anxiety about the symptoms improved 1.5 times faster than the symptoms did, which is the pattern an expectation effect makes, and it states no sample size, no placebo arm and no effect size. It is 1 unreplicated Russian-language paper from 2013. It is still 1 more than this product has.
The obstacle, and it is the cleanest one on this site. There is no translation chain here to examine. There is a tissue name, a class doctrine, and a price. What can be said about the compound is entirely inherited: the independent systematic review of this family pooled 24 randomized trials over 2,245 participants, judged risk of bias moderate to high and certainty of evidence low to very low, and covered cognitive endpoints rather than urological ones Alsulaimani 2021. Where a page has nothing of its own, the honest thing is to say the number rather than to fill the space, and the number is 0.
Vesilut pharmacokinetics — how much of it actually gets in
Two things on this card contradict each other, and the contradiction is the content. The half-life field says “Short (hrs systemically)”. The protocol says 1 injection a day for a 10-20 day course, then 3-6 months off. If the first is right the second is claiming an effect that outlives the molecule by a factor of tens of thousands, and no vendor selling this has ever been asked to reconcile them. Reconciling them is what this section does, and the number that matters turns out not to be the half-life.
What takes it apart, and where. This is a subcutaneous injection of an unsequenced peptide fraction, so there is no single clearance curve to quote — but every component of it is a short peptide with no chemical protection, and those all end the same way. Aminopeptidases sitting on the endothelial and interstitial surfaces the depot has to drain across strip residues off the N-terminus one at a time; what survives that meets the same enzymes again in plasma and in the kidney. Nothing in this preparation slows any of it down: no D-amino-acid substitutions, no cyclization, no terminal cap, no conjugated carrier. The reference case for what that protection is worth is somatostatin, whose plasma half-life Werle 2006 gives as a few minutes against 1.5 hours for octreotide — the same activity, deliberately shortened and D-substituted to survive. This product's fractions have octreotide's size and somatostatin's defencelessness. “Hrs systemically” is the wrong order of magnitude. Minutes is the defensible one.
The oral barrier, and the one page on this shelf that does not have to argue about it. Twelve neighbors in this catalog are capsules swallowed at 40-160 mg a day. This one is injected at 2-5 mg. Subcutaneous delivery skips both of the barriers those capsules cannot: the gut wall, where brush-border peptidases finish what gastric and pancreatic proteases start, and hepatic first pass, which the portal vein makes unavoidable for anything absorbed from the intestine. The carrier the class doctrine leans on to get through the first of those, PEPT1, moves di- and tripeptides Khavinson 2022 — 2 and 3 residues — and an uncharacterized fraction contains chains of many lengths, most with no carrier at all. The size of that barrier is not controversial: the only oral peptide ever to reach approval needed a permeation enhancer engineered around it Drucker 2020. Now take the two dose ranges at face value. 40-160 mg by mouth against 2-5 mg by needle is 8x to 80x more material for the swallowed route, which prices oral delivery at somewhere between 1% and 13% of what an injection gives. Nobody measured that. It is the vendors' own implied answer, built into a capsule size, and it is the strongest argument on this site for buying the injectable version of anything in this family.
The one quantity you can compute without a measurement. 5 mg into a 3 L plasma volume is 1.7 mg per liter. Assume a mean chain mass of 300 Da — roughly what a di- to tripeptide averages, and the only assumption in the calculation — and that is about 5.6 µM at the instant of injection, or 2.2 µM at the 2 mg end of the range. Treat it as a ceiling and not an estimate: it assumes the entire dose reaches plasma at once, distributes nowhere else, and has not begun to clear, none of which is true. The real peak is lower by an unmeasured amount. It is also, today, the only quantitative statement anyone can make about this product's exposure, because 0 plasma concentrations have ever been measured for it in any species.
Now the gap, which is the fact worth reading this page for. At a half-life of a few minutes, measurable drug exists for perhaps 20 minutes after each injection. Across a 20-day course at 1 injection a day that is on the order of 7 hours of drug inside 480 hours of protocol — about 1.5% of the course — followed by 3 to 6 months in which there is none at all. Nobody claims this product works for 20 minutes a day. The claim is that a course changes something for months. For both statements to be true the molecule cannot be the thing that persists; something it leaves behind has to be.
What would have to be true, stated as an inference and not as a finding. The Khavinson school's own answer is transcriptional: short peptides reach the nucleus, bind regulatory DNA and change what a cell makes Khavinson 2021. If that is right the peptide is a trigger and the durable object is a change in gene expression that outlives it — the same logic by which a hormone pulse lasting half an hour can set a state that runs for weeks. It is a coherent mechanism and it is the only one that reconciles the two halves of this card. It is also an inference from a class doctrine rather than a measurement on this product: there is no published transcript, methylation or protein read-out taken before and after a course of this preparation in any species. The experiment that would start closing the gap is small and needs no patients — 1 dose, 6 timed draws, mass spectrometry on the plasma — and it would give this whole family its first pharmacokinetic curve.
What would have to be true, and how you would know it was not
Three predictions. The first is about this product versus its sibling and it argues against buying this one.
1. Run the diary, and if you are choosing, choose on evidence. A 3-day bladder diary — voids per 24 hours, nocturia episodes, urgency episodes, volume per void — is the endpoint that matters and it costs nothing. Between 2 preparations aimed at the same tissue with the same absent composition, 1 has an indexed randomized study and 1 has nothing, and there is no published reason to expect them to differ chemically. The prediction is that a diary run across a course of either will look the same, and the decision rule that follows is to stop buying both.
2. A urinalysis first, every time. Urgency and frequency are the presentation of urinary tract infection; invisible blood in the urine is the presentation of bladder cancer, which is commoner in older smokers and presents exactly like an overactive bladder. This site's guidance is a urinalysis annually or with any kidney concern, and a new urinary symptom qualifies. No peptide mechanism predicts a change in it; it is there to catch what must not be self-treated.
3. Confirm the bladder is the organ before blaming it. Nocturia is often produced elsewhere: evening fluid and alcohol, untreated sleep apnea, heart failure, and high blood sugar causing osmotic diuresis. Fructosamine covers roughly the previous 2 to 3 weeks and this site retests it every 3 to 4 weeks during an active intervention; HbA1c covers 2 to 3 months and is retested every 3 months; in men PSA is the marker for the prostate cause of identical symptoms. If one of those is the reason, no bladder preparation can work, and the course will be read as a product failure when it was a diagnostic one.
What nobody has tested yet
Four experiments, and the first would take a week.
1. Nobody has compared the 2 bladder preparations. Chitomur and Vesilut are sold side by side for the same tissue. Run tandem mass spectrometry on 1 lot of each and compare the peptide profiles, chain length by chain length, down to 2 residues. If they are the same material, that is a finding buyers should have. If they differ, it is the first published compositional distinction between any 2 products in this catalog. 0 such comparisons have been published for any pair.
2. Nobody has looked for it in urine. The luminal argument above predicts that some fragment reaches the bladder from the kidney side. A urine sample after a dose, analyzed by mass spectrometry, tests it directly. This is the only tissue in the catalog whose surface can be sampled without a biopsy, and nobody has taken advantage of that.
3. Nobody has replicated the only positive trial in this space. A placebo-controlled repeat of the 2013 study with a stated sample size and a bladder diary endpoint would settle far more than any amount of further reading Gomberg 2013, and it would tell you whether this product's sibling deserves its position.
4. Nobody has measured post-void residual on any of them. It is a bedside ultrasound, it takes under 5 minutes, it is the safety measurement for any bladder intervention, and it appears in 0 published reports on this family.
Vesilut — its own safety story, not its class's
Three things specific to a bladder preparation, and none of them are in the class block.
Blood in the urine ends the peptide conversation. Hematuria in an adult, especially a current or former smoker over 50 years, warrants imaging and cystoscopy for bladder and kidney cancer. It is often invisible and it is found on a urinalysis. This is the symptom on this page where months of delay have a measurable cost.
Worsening on a course is a reason to measure, not to persist. Incomplete bladder emptying causes infection and, if severe, kidney damage, and it presents as the same frequency and urgency this product is bought for. Post-void residual volume settles it in minutes and has never been reported in any study of this family.
What zero means here. There are 0 published adverse events for this product, and 0 human studies of it, so no setting has existed in which an adverse event could have been recorded. The related product's single trial reported no side effects detected, which is a real observation from 1 study of unstated size in older women and cannot detect anything uncommon. Animal-tissue origin adds a sourcing question the synthetic peptides in this catalog do not carry, and no vendor publishes a composition that would let anybody check it.
Sources read for this page
- Gomberg VG, Ryzhak AP, Lyutov RV. Correction of age related bladder function decrease with peptide geroprotector in women. Advances in Gerontology 2013;26(2):309–314 · PMID 28976156
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006 · PMID 16622600
- Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery 2020 · PMID 31848464
Vesilut — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Vesilut — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Vesilut moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Vesilut in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Vesilut
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Vesilut — frequently asked questions
What is Vesilut?
Vesilut (Bladder bioregulator) is a longevity & bioregulators research compound. Khavinson urinary-bladder bioregulator — proposed to support bladder cell function and urogenital aging.
Is the full Vesilut protocol on this page?
The reported research dose is on this page, along with how Vesilut works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Vesilut?
Vesilut has an approximate half-life of Short (hrs systemically), which is part of what determines how often it's dosed.
What's the evidence behind Vesilut?
Current evidence level: Russian studies; limited. Vesilut is offered for research purposes only and is not an approved medicine.
What Vesilut is used for
Vesilut appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.